Baseline patient characteristics
| Patient no. . | 1 . | 2 . | 3 . | 4 . | 5 . | 6 . |
|---|---|---|---|---|---|---|
| Age, y/sex | 51/M | 47/F | 64/F | 49/M | 66/M | 68/M |
| MF type | PMF | Post-PVMF | Post-PVMF | Post-ETMF | Post-ETMF | Post-PVMF |
| Disease duration, y | 3 | 4 | 4 | 4 | 1 | 4 |
| Years after splenectomy | 1 | 5 | 4 | NA | NA | 20 |
| Hepatomegaly | No | 16cm | 14cm | No | No | 16cm |
| ECOG | 1 | 1 | 1 | 1 | 1 | 1 |
| Risk DIPSS plus | High | Int-2 | High | Int-2 | Int-2 | High |
| No. of prior therapies | 5 | 0 | 2 | 1 | 2 | 3 |
| Hematologic findings | ||||||
| WBC, K/UL | 18.6 | 91.6 | 7.9 | 13.8 | 7.3 | 63.9 |
| Hb, g/dL | 9.0 | 13.4 | 10.8 | 9.0 | 11.3 | 8.7 |
| PLT, K/UL | 394 | 575 | 197 | 728 | 1135 | 536 |
| Transfusion need | Yes | No | Yes | No | No | Yes |
| PB blast % | 9 | 1 | 0 | 0 | 0 | 0 |
| Bone marrow | ||||||
| Blast % | 11 | 1 | 0 | 8 | 0 | 1 |
| Cytogenetics | 3q−, 11q−, 15q−, 20q− | 46XX | 13q−, 20q− | 46XY | 46XY | t(6,12),+8, 20q− |
| Molecular data | ||||||
| JAK2V617F mutation status | − | + | + | + | − | + |
| JAK2V617F allele burden | 0 | 92 | 49 | 45.6 | 0 | 96 |
| Patient no. . | 1 . | 2 . | 3 . | 4 . | 5 . | 6 . |
|---|---|---|---|---|---|---|
| Age, y/sex | 51/M | 47/F | 64/F | 49/M | 66/M | 68/M |
| MF type | PMF | Post-PVMF | Post-PVMF | Post-ETMF | Post-ETMF | Post-PVMF |
| Disease duration, y | 3 | 4 | 4 | 4 | 1 | 4 |
| Years after splenectomy | 1 | 5 | 4 | NA | NA | 20 |
| Hepatomegaly | No | 16cm | 14cm | No | No | 16cm |
| ECOG | 1 | 1 | 1 | 1 | 1 | 1 |
| Risk DIPSS plus | High | Int-2 | High | Int-2 | Int-2 | High |
| No. of prior therapies | 5 | 0 | 2 | 1 | 2 | 3 |
| Hematologic findings | ||||||
| WBC, K/UL | 18.6 | 91.6 | 7.9 | 13.8 | 7.3 | 63.9 |
| Hb, g/dL | 9.0 | 13.4 | 10.8 | 9.0 | 11.3 | 8.7 |
| PLT, K/UL | 394 | 575 | 197 | 728 | 1135 | 536 |
| Transfusion need | Yes | No | Yes | No | No | Yes |
| PB blast % | 9 | 1 | 0 | 0 | 0 | 0 |
| Bone marrow | ||||||
| Blast % | 11 | 1 | 0 | 8 | 0 | 1 |
| Cytogenetics | 3q−, 11q−, 15q−, 20q− | 46XX | 13q−, 20q− | 46XY | 46XY | t(6,12),+8, 20q− |
| Molecular data | ||||||
| JAK2V617F mutation status | − | + | + | + | − | + |
| JAK2V617F allele burden | 0 | 92 | 49 | 45.6 | 0 | 96 |
MF indicates myelofibrosis; PMF, primary myelofibrosis; post-PVMF, postpolycythemia vera myelofibrosis; post-ETMF, postessential thrombocytosis myelofibrosis; PB, peripheral blood; and NA, not applicable